GB201907832D0 - Medical uses, methods and uses - Google Patents
Medical uses, methods and usesInfo
- Publication number
- GB201907832D0 GB201907832D0 GBGB1907832.8A GB201907832A GB201907832D0 GB 201907832 D0 GB201907832 D0 GB 201907832D0 GB 201907832 A GB201907832 A GB 201907832A GB 201907832 D0 GB201907832 D0 GB 201907832D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- methods
- medical
- medical uses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907832.8A GB2584441A (en) | 2019-06-03 | 2019-06-03 | Medical uses, methods and uses |
| PCT/EP2020/065295 WO2020245160A1 (en) | 2019-06-03 | 2020-06-03 | Medical uses, methods and uses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907832.8A GB2584441A (en) | 2019-06-03 | 2019-06-03 | Medical uses, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201907832D0 true GB201907832D0 (en) | 2019-07-17 |
| GB2584441A GB2584441A (en) | 2020-12-09 |
Family
ID=67385908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1907832.8A Withdrawn GB2584441A (en) | 2019-06-03 | 2019-06-03 | Medical uses, methods and uses |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2584441A (en) |
| WO (1) | WO2020245160A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114763574A (en) * | 2021-01-12 | 2022-07-19 | 浙江省肿瘤医院 | CDKN2A/2B deficiency as biomarker for predicting sensitivity of CDK4/6 inhibitor in esophageal squamous carcinoma |
| CN119454975B (en) * | 2024-12-02 | 2025-10-21 | 中国医学科学院医学实验动物研究所 | Application of a pharmaceutical composition in treating cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874A (en) | 1848-10-24 | Apparatus eob baking- water | ||
| US541A (en) | 1837-12-26 | Daniel desmond | ||
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| PT1589107E (en) | 1992-08-21 | 2010-03-29 | Univ Bruxelles | IMMUNOGLOBULINS FOR LIGHT CHAINS |
| US5716081A (en) | 1996-03-11 | 1998-02-10 | Automotive Products (Usa), Inc. | Spring clip for quick connect coupling |
| CA2258518C (en) | 1996-06-27 | 2011-11-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| WO2008036254A2 (en) * | 2006-09-18 | 2008-03-27 | The General Hospital Corporation | Autophagic compounds and tyrosine kinase inhibitors for treating cancer |
| EP2134860A1 (en) * | 2007-04-13 | 2009-12-23 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to kinase inhibitors |
| WO2008127659A2 (en) * | 2007-04-13 | 2008-10-23 | University Of Texas Southwestern Medical Center | Combination therapy for cancer |
| EP2971092B1 (en) * | 2013-03-15 | 2020-04-22 | Life Technologies Corporation | Prognostic assay for squamous cell lung carcinoma |
| EP3528798A4 (en) * | 2016-10-19 | 2020-10-21 | United States Government as Represented by The Department of Veterans Affairs | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER |
| WO2018092064A1 (en) * | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| CN107843021B (en) * | 2017-11-13 | 2019-07-30 | 大连理工大学 | A double-layer nozzle and double-row tube gas-wave refrigerator with built-in drive hydraulic balance |
-
2019
- 2019-06-03 GB GB1907832.8A patent/GB2584441A/en not_active Withdrawn
-
2020
- 2020-06-03 WO PCT/EP2020/065295 patent/WO2020245160A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB2584441A (en) | 2020-12-09 |
| WO2020245160A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275055A (en) | Triabody, preparation method and use thereof | |
| PT3546457T (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| EP3316824A4 (en) | Compression implants, instruments and methods | |
| EP3261501A4 (en) | Soft, strong and bulky tissue | |
| GB201904104D0 (en) | Composition, method and use | |
| GB2591554B (en) | Composiitons and methods and uses relating thereto | |
| ZA202103259B (en) | Modified cas9 protein, and use thereof | |
| IL276952A (en) | 2,4-diaminoquinazoline derivatives and medical uses thereof | |
| GB201916246D0 (en) | Compositons, and methods and uses relating thereto | |
| IL271728A (en) | Agents, uses and methods for treatment | |
| GB201709840D0 (en) | Methods and medical uses | |
| ZA202007187B (en) | Solubilized apyrases, methods and use | |
| IL290037A (en) | Ergothioneine, s-methyl-ergothioneine, and uses thereof | |
| GB201909486D0 (en) | Compositons, uses and methods | |
| GB2564511B (en) | Composition, method and use | |
| GB202002352D0 (en) | Hygiene compliance method, use and system | |
| EP3263010A4 (en) | Over-tube for endoscope, and medical system | |
| HUE046471T2 (en) | Polybutadienes, their preparation and use | |
| GB201810165D0 (en) | Surgical assembly, system and electrode assembly | |
| GB201910299D0 (en) | Medical uses, methods and uses | |
| GB201907832D0 (en) | Medical uses, methods and uses | |
| GB201805016D0 (en) | Composition, method and use | |
| GB2579240B (en) | New processes, compositions and medical uses | |
| GB201715724D0 (en) | Devices,and methods and uses relating thereto | |
| HK40042253A (en) | Solubilized apyrases, methods and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| COOA | Change in applicant's name or ownership of the application |
Owner name: FENOMARK DIAGNOSTICS AB Free format text: FORMER OWNERS: JANNE LEHTIOE;LUKAS MINUS ORRE |
|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |